Dreaded “portfolio prioritisation” at BMS sees end to ADC deal with Eisai
抗体药物偶联物临床2期临床1期
Ongoing “portfolio prioritisation” efforts at Bristol Myers Squibb have scuppered a deal with Eisai to develop the Japanese pharm’s antibody-drug conjugate farletuzumab ecteribulin. Eisai said Monday that it now owns all rights to the folate receptor alpha (FRα)-targeting therapy and will conduct development alone.
Bristol Myers Squibb paid $650 million upfront back in 2021 to co-develop farletuzumab ecteribulin, then known as MORAb-202, as part of an alliance potentially worth over $3 billion. The ADC combines Eisai's humanised IgG1 monoclonal antibody farletuzumab, which binds to FRα, with its anticancer agent Halaven (eribulin), using an enzyme cleavable linker.
Farletuzumab ecteribulin is currently being evaluated in Phase II studies for non-small-cell lung, ovarian, peritoneal and fallopian tube cancers, as well as a Phase I/II trial for solid tumours. Eisai said Monday that it plans to “accelerate” the development of the agent as a high priority.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。